TWD 675.0
(3.05%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 5.73 Billion TWD | 112.92% |
2022 | 2.27 Billion TWD | 76.58% |
2021 | 1.28 Billion TWD | 247.53% |
2020 | 370.53 Million TWD | -18.03% |
2019 | 452.03 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 1.1 Billion TWD | -21.19% |
2024 Q1 | 1.2 Billion TWD | 33.68% |
2023 Q2 | 1.2 Billion TWD | -25.71% |
2023 Q4 | 902.98 Million TWD | -19.01% |
2023 FY | - TWD | 112.92% |
2023 Q1 | 1.62 Billion TWD | 113.25% |
2023 Q3 | 1.11 Billion TWD | -7.36% |
2022 Q3 | 711.91 Million TWD | 0.0% |
2022 FY | - TWD | 76.58% |
2022 Q4 | 759.73 Million TWD | 6.72% |
2021 FY | - TWD | 247.53% |
2020 FY | - TWD | -18.03% |
2019 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Grape King Bio Ltd | 2.88 Billion TWD | -98.763% |
Standard Chem & Pharm CO., LTD. | 1.57 Billion TWD | -263.163% |
Maywufa Company Ltd. | 239.81 Million TWD | -2291.125% |
ScinoPharm Taiwan, Ltd. | 819.15 Million TWD | -600.021% |
Lotus Pharmaceutical Co., Ltd. | 6.87 Billion TWD | 16.544% |
LIWANLI Innovation Co., Ltd. | 6.81 Million TWD | -84103.407% |
YungShin Global Holding Corporation | 1.35 Billion TWD | -322.455% |
PhytoHealth Corporation | -20.69 Million TWD | 27804.377% |
SCI Pharmtech, Inc. | 529.61 Million TWD | -982.725% |
Formosa Laboratories, Inc. | 1.16 Billion TWD | -392.928% |
PharmaEssentia Corporation | -671.48 Million TWD | 953.964% |